KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Other Non-Current Assets (2020 - 2025)

Bionano Genomics' Other Non-Current Assets history spans 5 years, with the latest figure at $2.8 million for Q4 2024.

  • For Q4 2024, Other Non-Current Assets fell 62.94% year-over-year to $2.8 million; the TTM value through Dec 2024 reached $2.8 million, down 62.94%, while the annual FY2024 figure was $2.8 million, 62.94% down from the prior year.
  • Other Non-Current Assets for Q4 2024 was $2.8 million at Bionano Genomics, up from $400000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $7.4 million in Q4 2023 and bottomed at $103000.0 in Q4 2020.
  • The 5-year median for Other Non-Current Assets is $400000.0 (2022), against an average of $1.4 million.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 1757.75% in 2023 before it plummeted 62.94% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $103000.0 in 2020, then surged by 627.18% to $749000.0 in 2021, then plummeted by 46.6% to $400000.0 in 2022, then surged by 1757.75% to $7.4 million in 2023, then tumbled by 62.94% to $2.8 million in 2024.
  • Per Business Quant, the three most recent readings for BNGO's Other Non-Current Assets are $2.8 million (Q4 2024), $400000.0 (Q1 2024), and $7.4 million (Q4 2023).